Circulating tumor DNA (ctDNA) to detect neuroendocrine prostate cancer genomic and DNA methylation changes.

Himisha Beltran

A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.

Frederic Pouliot

Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial.

Piet Ost

Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.

Julie Nicole Graff

Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.

Karim Fizazi

The association between PSA pattern changes and progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone and prednisone (AA/P).

Iris Yeong- Fung Sheng

Impact of 18F-fluciclovine PET on salvage radiotherapy plans for men with post-radical prostatectomy recurrence of prostate cancer.

Heather Ann Payne

The effect of androgen deprivation therapy on 68GA-PSMA-tracer uptake in nonmetastatic prostate cancer patients.

Onal Cem

FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC).

Katherine A. Zukotynski

Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer.

Carissa Chu

A deep learning algorithm to predict coexisting metastatic disease using intraprostatic [F18]DCFPYL PSMA image alone in veterans with prostate cancer.

Nicholas George Nickols

A multivariate logistic regression model based on 3T mpMRI, clinical, and biopsy parameters for the prediction of prostate cancer extracapsular extension.

Sohrab Afshari Mirak

Non-prostate cancer malignancies detected by 18F-Fluciclovine PET/CT.

Andrew R. Barsky

Real-world management of advanced prostate cancer: A Canadian comparison of academic specialists and community-based prostate cancer physicians.

Sebastien J. Hotte

Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.

Edoardo Francini

Late dosing of luteinizing hormone-releasing hormone agonists (LHRH) and testosterone (T) levels >20 ng/dL in prostate cancer (PCa).

Przemyslaw Twardowski

Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).

Celestia S. Higano

Real-world analysis of prostate-specific antigen (PSA) outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA).

Stephen J. Freedland

Edmonton Prostate Interdisciplinary Cancer Clinic (EPICC): Real-world efficacy outcomes of a multidisciplinary clinic for metastatic castration-resistant prostate cancer.

Graeme Follett

Long-term health-related quality-of-life outcomes in a racially diverse cohort of prostate cancer patients receiving retropubic versus robotic prostatectomy.

Galen Conti

5-alpha reductase inhibitors (5-ARI) and prostate cancer mortality among men with regular access to screening and health care.

Lorelei A. Mucci

Overall survival (OS) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving bicalutamide (BIC) followed by enzalutamide (ENZA) or abiraterone (ABI).

Daniel J. George

Fracture rates in radium223 (Ra223) treated mCRPC patients (pts): A real-world analysis in 177 pts treated at a single community center 2010-2018.

Yen Thi Kim Hong Cao

Overall survival (OS) among Medicare beneficiaries receiving sipuleucel-T (sip-T) versus oral treatment for metastatic castration-resistant prostate cancer (mCRPC).

Rana R. McKay

Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC).

Jacob E Berchuck

Prevalence and clinical impact of BRCA1/2 mutations in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC).

Nieves Martinez Chanza

Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).

Panagiotis J. Vlachostergios

Real-world survival improvements in patients with newly diagnosed metastatic prostate cancer treated in the United States.

Carlo Cattrini

Association of area social determinants of health with prostate cancer mortality.

John Clark Henegan

Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant pros

Neal D. Shore

A risk scoring system for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line abiraterone (ABA) or enzalutamide (ENZ).

Jacqueline T Brown

The real-world efficacy of abiraterone acetate (ABA) and docetaxel (DOC) in the treatment of African-American (AA) patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC).

Katherine E.R. Smith

Health-related quality of life (HRQoL) patient-reported outcomes (PROs) and survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).

Lorente David

Veterans affairs (VA) prostate cancer treatment (Tx) sequencing (VAPCaTS): A real-world study.

Stephen J. Freedland

Variance in symptom assessment between patient and caregiver: A prospective study of patients staged as metastatic prostate cancer—An interim analysis.

Sadie Swift

Health care team and treatment decision-making experiences among prostate cancer patients.

Nicole E. Nicksic

The National Radium-223 Dichloride Audit Group: Data from patients in United Kingdom oncology centers with metastatic castration-resistant prostate cancer treated with radium-223 dichloride.

Manreet Randhawa

Using natural language processing (NLP) tools to identify veterans with metastatic prostate cancer (mPCa).

Patrick R. Alba

A retrospective review of the effect of metformin in metastatic prostate cancer.

So Yi Lam

Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.

Alexandra Sokolova

Genomic profiling of prostate cancer at a diverse academic center.

Robert Lopez

Tumor protein expression of BRCA1 and development of lethal prostate cancer.

Carl Ceraolo

Mental perception of prostate cancer (PCa) disease in patients aged 60 years and older initiating gonadotropin-releasing hormone agonist (GnRHa) therapy.

Christophe Hennequin

Financial hardship among Medicare beneficiaries prescribed oral targeted therapies for advanced prostate cancer.

Megan Veresh Caram

Epidemiology and regional variation in the mortality of patients admitted with prostate cancer in the United States.

Arya Mariam Roy

Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factors (GCSF) in Chinese metastatic hormonal-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC).

Darren M.C. Poon

The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC).

Shabbir M.H. Alibhai

Predicting toxicity-related docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer (mCRPC) using open phase III trial data.

Anish B. Parikh

Exenterative surgery to improve quality of life on men with locally advanced, symptomatic castration-resistant prostate cancer.

Friederike Haidl

Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.

Andrew Lachlan Schmidt

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): A multicenter phase I study.

Marit Vermunt

Propensity score matched comparison of docetaxel and androgen receptor axis-targeted (ARAT) agents in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate (IDC-P).

Akiyuki Yamamoto

The use of intermittent enzalutamide dosing in the treatment of metastatic castrate-resistant prostate cancer.

Michael Rowe

Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane).

Neeraj Agarwal

PT-112 in advanced metastatic castrate-resistant prostate cancer (mCRPC), as monotherapy or in combination with PD-L1 inhibitor avelumab: Findings from two phase I studies.

Alan Haruo Bryce

Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC).

Susan F. Slovin

Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1).

Marijo Bilusic

Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC).

Julie Nicole Graff

Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease.

Mustafa Ozguroglu

SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study.

Xiaojian Qin

Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC).

Anthony Serritella

Impact of upstream use of novel hormonal therapy on progression of patients (pts) to metastatic castration-resistant prostate cancer (mCRPC) in the United States (US).

Howard I. Scher

Oligopelvis-GETUG P07: A multicenter phase II trial of combined salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses of prostate cancer.

Stephane Supiot

Phase II trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.

Mitchell E. Gross

Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial.

Miguel Angel Climent Duran

Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).

Tian Zhang

Phase II trial of a novel immunotherapy combination of pembrolizumab and HER2 bi-armed activated T cells (BATs) in metastatic castrate resistant prostate cancer.

Meera Patel

MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.

Johann S. De Bono

KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Evan Y. Yu

Prostate-directed radiation therapy and overall survival for men with M1a prostate cancer.

David Dewei Yang

KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

William R. Berry

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

Michael Paul Kolinsky

Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC).

Emmanuel S. Antonarakis

PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.

Shruti U. Gandhy

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC).

Risa Liang Wong

Association of tumor burden with the eligibility of upfront therapy in patients with castration-naive prostate cancer: A multicenter retrospective study.

Hiromichi Iwamura

Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1).

Antonin Broyelle

Analysis of the prognostic significance of circulating tumor DNA (ctDNA) in metastatic castrate-resistant prostate cancer (mCRPC).

Justin Shaya

Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

Joseph W. Kim

Systemic therapy for nonmetastatic castrate-resistant prostate cancer (M0 CRPC): A systematic review and network meta-analysis (NMA).

Ellen Cusano

Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

Scott T. Tagawa

Association of body composition with survival and efficacy of first-line treatment in patients with castration-resistant prostate cancer.

Jae Young Joung

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Phuoc T. Tran

Analysis of prevalence and prognostic implications of early versus delayed PSA declines during radium-223 (Ra223) treatment among men with metastatic castration-resistant prostate cancer (mCRPC).

Amanjot Sidhu

Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.

Matthew Raymond Smith

TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).

Johann S. De Bono

Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).

Louise Emmett

Overall survival using radium-223 (Ra223) in metastatic castrate-resistant prostate cancer (mCRPC) patients with and without DNA damage repair (DDR) defects.

Maarten J. van der Doelen

Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Fred Saad

Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide + docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial.

Orazio Caffo

Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC).

Horst-Dieter Hummel

Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints.

Benjamin Louis Maughan

KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel.

Mark N. Stein

A pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the BRCA1/2 pathway.

Heather H. Cheng

Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC).

Lauren Christine Harshman

Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).

Catherine Handy Marshall

Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.

Amanda Elizabeth Hird

Revision of CHAARTED and LATTITUDE criteria among Japanese de novo metastatic prostate cancer patients.

Shinichi Sakamoto

The effect of AKR1C3 on the switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients receiving abiraterone.

Yuchao Ni

PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

Johann S. De Bono

Surgical management versus combination radiotherapy in Gleason score 9-10 prostate cancer.

Edward Christopher Dee

Clinical investigation of neuroendocrine differentiation in prostate cancer.

Tatsuya Shimomura

Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study.

Neeraj Agarwal

Safety of BXCL701, a small molecule inhibitor of dipeptidyl peptidases (DPP), with pembrolizumab, (pembro, anti-PD-1) monoclonal antibody, in men with metastatic castration-resistant prostate cancer (mCRPC).

Rahul Raj Aggarwal

IND candidate EPI-7386 as an N-terminal domain androgen receptor inhibitor in development for the treatment of prostate cancer.

Ronan Le Moigne

Role of metastases-directed therapy (MDT) in the management of solitary metastatic prostate cancer.

Mohamed E. Ahmed

Non-rising PSA disease progression on C-11 choline PET/CT imaging in patients receiving second generation hormone therapies (2nd-HT).

Mohamed E. Ahmed

ADRB2 expression in progressive metastatic castration-resistant prostate cancer.

Daniel Kwon

A prospective study of the relationship between clinical outcomes of enzalutamide and serum androgen levels measured by LC-MS/MS in patients with CRPC.

Yoshiyuki Miyazawa

Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC).

Santosh Gupta

The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer.

Yuki Yoshikawa

Checkpoint kinase inhibition in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors.

Mohammad Omar Atiq

New patient-derived models of castrate-sensitive and castrate-resistant prostate cancer.

Mitchell Lawrence

The tumor immune microenvironment of germline BRCA1/2 and sporadic prostate cancer.

Anna S. Trigos

Gene expression in circulating tumor cells (CTC) and plasma androgen receptor (AR) gene copy number (CN) for castration-resistant prostate cancer (CRPC) patients (pts) treated with cabazitaxel.

Giorgia Gurioli

Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa).

Katherine L. Paweletz

Linking the Aggressive Variant Prostate Cancer (AVPC) molecular signature (-ms) to androgen indifference in a prospective clinical trial.

Paul Vincent Viscuse

Defining the monocyte subset transcriptional signature associated with progression during androgen-target therapy in prostate cancer patients.

Karen Angelica Cavassani

Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)—Resul

Eric Jay Small

Plasma circulating tumor DNA (ctDNA) based clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC).

Manish Kohli

Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.

Anis Hamid

MicroRNA-based biomarkers of the radiation response in prostate cancer.

Joanne B. Weidhaas

Association of high plasma glutamine levels with outcome in metastatic castration-resistant prostate (mCRPC) patients treated with taxanes.

Veronica Pereira Diaz

Association of neuroendocrine (NE) mRNA expression profiling in hormone-sensitive tumors samples with adverse clinical outcome in castration-resistant prostate cancer (CRPC) patients.

Mayra Orrillo

Targeting tumor-associated macrophage (TAM) mediated inhibition of T-cell migration in prostate cancer using epigenetic modifying agents.

David Kosoff

Genomic alterations in visceral versus nonvisceral “metastatic” site tumor tissue in metastatic prostate cancer (mPC).

John Esther

Association of very small nuclear circulating tumor cell (vsnCTC) with clinical outcomes in metastatic castration-resistant prostate cancer.

Jasmine Jiemei Wang

Prostate cancer CTC-RNA Assay: A new method for contemporary genomics and precision medicine via liquid biopsy.

Pai-Chi Teng

Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805).

Lauren Christine Harshman

Impact of DNA damage repair (DDR) mutations on treatment outcomes in men receiving conventional therapy for metastatic castration resistant prostate cancer (mCRPC).

Alex S. Carlson

Circulating tumor DNA-targeted sequencing to reveal germline and somatic alterations that can guide decision-making in metastatic castration-resistant prostate cancer.

Baijun Dong

Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC).

Edoardo Francini

Plasma cell-free DNA (cfDNA) profiling of copy number variation (CNV) to identify poor prognostic biomarkers in metastatic castration-resistant prostate cancer (mCRPC).

Edmond Michael Kwan

The effect of abiraterone acetate treatment on CREB and the development of abiraterone acetate resistance in prostate cancer cells.

Wenting Pan

Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).

Wassim Abida

Copy number amplification of androgen receptor in cell-free DNA is a potential prognostic factor in patients with CRPC.

Itsuto Hamano

CDK12 upregulation and adverse correlation with tumor-associated immune cell infiltrates in prostate cancer.

Marie C. Hupe

Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).

Zhen Shi

Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.

Landon Carter Brown

Assessment of inherited DNA repair defects in African-American and Caucasian men with prostate cancer.

A. Oliver Sartor

Biomarker analysis (CTC and ctDNA/RNA) of GT0918 (Proxalutamide) new AR blocker in phase I mCRPC patients with dose escalation.

Karl Zhou

Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations.

Daniel Kwon

Testosterone recovery as biomarker for overall and cause-specific survival in combined treated patients with high-risk and locally advanced prostate cancer.

Mathew Deek

Molecular underpinnings of RB status as a biomarker of poor outcome in advanced prostate cancer.

Amy C. Mandigo

Circulating tumor (ct) DNA-based comprehensive genomic profiling to identify microsatellite instability (MSI) and defective DNA damage repair (DDR) in prostate cancer (PCa) patients.

Leylah M. Drusbosky

<i>CDK12</i>-mutated prostate cancer (PC): Clinical outcomes to standard therapies and immune checkpoint blockade.

Michael Thomas Schweizer

MiR-27a-3p: An AR-modulatory microRNA with a distinct role in prostate cancer progression and therapy.

Foteini Kalofonou

Mismatch repair deficiency in metastatic prostate cancer (PC): Response to PD-1 blockade and standard therapies.

Laura Graham

Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience.

Maha H. A. Hussain

High-exosomal AKR1C3 mRNA expression as a marker of poor efficacy of abiraterone in metastatic PCa patients.

Sha Zhu

Androgen receptor cfDNA longitudinal mutational analysis in metastatic castrate-resistant prostate cancer.

Elisa Marie Ledet

Comparison of Caucasian and African-American DNA repair alterations in men with metastatic prostate cancer.

Ellen Jaeger

Circulating tumor DNA (ctDNA) landscape in metastatic castrate-resistant prostate cancer patients with germline alterations.

Marcus W. Moses

Elevated circulating CCL2 in prostate cancer patients.

Justin Lin

Biomarkers of prolonged time to treatment failure in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A real life patients-based nomogram and web app.

Maysa Tamara Silveira Vilbert

Characterization of Wnt signaling pathway (WSP) aberrations in advanced prostate cancer.

Fady Ghali

Addition of abiraterone to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Model to estimate long-term survival, quality-adjusted survival, and cost-effectiveness.

Caroline Sarah Clarke

Androgen deprivation therapy and statin therapy in prostate cancer patients.

Kin Chung Lai

Relationship between Geriatric 8 screening score and treatment selection in patients with prostate cancer.

Shingo Hatakeyama

The psychological impact of early prostate cancer: A prospective evaluation.

Hadas Dresler

Cost-effectiveness of upfront therapeutic options in low-volume de novo metastatic hormone-sensitive prostate cancer.

Neil Rohit Parikh

Prognostic value of novel inflammation index for patients with metastatic castration-resistant prostate cancer.

Yasutaka Yamada

The impact of time-to-castration resistance on survival in patients with metastatic hormone-naïve prostate cancer: A multicenter retrospective study.

Teppei Okamoto

Role of soft tissue metastases on tumor progression in castrate-resistant metastatic prostate cancer.

Kathleen Ruchalski

Evaluation of bone metastasis and prognosis of prostate cancer with bone metastasis during standard hormonal therapy and chemotherapy: A report of PROSTAT-BSI multicenter registry in Japan.

Atsushi Mizokami

[18F]Fluciclovine-PET/MRI use in monitoring response to androgen deprivation therapy in men with prostate cancer following initial staging.

Samuel Joseph Galgano

The role of 68Ga-DOTATATE for evaluation of patients with metastatic castration-resistant prostate cancer (mCRPC).

Mehmet Asim Bilen

Radiotherapy (RT) guided by ultra‐small superparamagnetic iron oxide (USPIO)-contrast MRI staging for patients with advanced or recurrent prostate cancer.

Yun Rose Li

Comparative efficacy of local versus systemic salvage therapies for recurrent prostate cancer after primary radiotherapy.

Glenn Bauman

Extension of bone marrow involvement and cytopenias in patients with metastatic castration-resistant prostate cancer (mCRPC).

Daniel D Almeida Preto

Real-world utilization of radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A U.S. tertiary oncology center analysis.

Rana R. McKay

Treatment decision making in metastatic prostate cancer (mPC).

Alicia K. Morgans

Prognostic factors that affect survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223.

Esmail Mutahar Al-Ezzi

Preliminary outcomes of a prospective observational study of combinatorial abiraterone acetate/enzalutamide (AA/Enz) and radical radiotherapy (RT) in nonmetastatic node-positive (N+M0) prostate cancer (PCa).

Mark Ting Le Tan

Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience.

Niamh Peters

Review of the real-world prevalence of mHSPC, nmCRPC, mCRPC, and gene alterations associated with HRR in prostate cancer (PC).

Neal D. Shore

Factors associated with positive germline testing results in men with prostate cancer following NCCN guideline expansion.

Trevor Charles Hunt

Family history and germline alterations in metastatic prostate cancer patients.

Whitley Hatton

Quality of life of prostate cancer (PCa) patients with testosterone deficiency symptoms (TDS) before initiation of gonadotropin-releasing hormone (GnRH) agonist therapy: Subgroup analysis of EQUINOXE study.

Stephane Droupy

The impact of race and insurance status on survival of prostate cancer patients.

Trevanne Rose Matthews Hew

Survey of ADT-induced estrogen deficiency-related side effects in a contemporary cohort of men with advanced prostate cancer.

Robert H. Getzenberg

Safety and effectiveness of radium-223 dichloride (Ra-223) in patients with mCRPC in real-world setting: A Japanese post-marketing study (PMS).

Shunji Takahashi

Lymph node metastasis to predict overall survival in oligometastatic prostate cancer in Asian patients.

Junryo Rii

The effect of treatment sequence on overall survival for men with metastatic castration-resistant prostate cancer: A multicenter retrospective study.

Shingo Hatakeyama

Efficacy of sequential therapy comprising of docetaxel, abiraterone, enzalutamide, and cabazitaxel in patients with castration-resistant prostate cancer.

Akiyuki Yamamoto

The efficacy of metastasis-directed radiation therapy (MDRT) for oligometastatic castration-resistant prostate cancer (CRPC).

Akira Nagahara

Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.

Itsuto Hamano

Blood platelet volume to predict treatment-specific outcomes of metastatic castration-resistant prostate cancer.

Wataru Fukuokaya

Effect of core needle biopsy number on intraductal carcinoma diagnosis in patients with metastatic castration-sensitive prostate cancer.

Masashi Kato

Prevalence of ARV7 in Asian metastatic castrate-resistant prostate cancer (mCRPC) patients using multiple detection platforms.

Johan Chan

Preliminary results of a prospective assessment of androgen receptor splice variants in mCRPC patients undergoing androgen receptor targeted agents.

Giulio Francolini

Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer.

Shintaro Narita

Characterization of metastatic spinal cord compression from prostate cancer.

Jianbo Wang

Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.

Felix Y Feng

Analysis of small non-coding RNAs in urinary exosomes to classify prostate cancer into low-grade (GG1) and higher-grade (GG2-5).

Laurence Klotz

Evaluation of Proclarix, a prostate cancer risk score, used together with magnetic resonance imaging for the diagnosis of clinically significant prostate cancer.

Halyey Pye

Artificial intelligence for streamlined immunofluorescence-based biomarker discovery in prostate cancer.

Claire Marie de la Calle

Integrating comprehensive genomic profiling into the clinical management of prostate cancer patients: A single institution community practice experience.

Neal D. Shore

Pathologic outcomes of MRI invisible tumors in prostate cancer.

Sandeep Gurram

Does size matter? Lesion size as an indicator of number of cores needed to detect clinically significant prostate cancer.

Amir H. Lebastchi

TMPRSS2: ERG expression in prostate cancer—Imaging and clinicopathological correlations.

Vittorio Fasulo

A phase IIa randomized placebo-controlled trial of pomegranate fruit extract/POMx in subjects with clinically localized prostate cancer undergoing active surveillance.

David Frazier Jarrard

Detection of significant prostate cancer through magnetic resonance imaging targeted biopsy of PI-RADS3 lesions in African American patients based on prostate specific antigen density threshold of 0.15 ng/ml²: Analysis of patient population from the Vatti

Shaheen Riadh Alanee

Detection of clinically significant prostate cancer after negative fusion and systematic biopsy.

Jeffrey Twum-Ampofo

Advancing age and the risk of adverse pathology at radical prostatectomy in men with biopsy Gleason score 6 prostate cancer.

Daniel Kim

Risk factors which predict biopsy upgrading over time in active surveillance for prostate cancer.

Peter Eoin Lonergan

GLUT1 expression in high-risk prostate cancer: Correlation with 18F-FDG-PET/CT and clinical outcome.

Frederic Pouliot

Association of PI-RADS categories and PSA density with active surveillance progression in patients with prostate cancer.

Alex Z. Wang

Characterization of PSMA and 18F-fluciclovine transporter gene expression in localized prostate cancer.

Carissa Chu

Comparison of micro-ultrasound and multiparametric MRI imaging for prostate cancer: A multicenter prospective analysis.

Laurence Klotz

Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer.

Hala Borno

Clinical utility of PSA density and PI-RADS for deferring biopsy for the detection of clinically significant prostate cancer.

Matthew Truong

18-year prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer.

Annika Herlemann

PSA status after neoadjuvant androgen deprivation therapy before high-dose-rate brachytherapy as biomarker for prediction of long-term outcome in high-risk prostate cancer patients.

Trude Wedde

Acute patient-reported toxicities after proton therapy or intensity-modulated radiotherapy for prostate cancer.

Kimberly Gergelis

Influence of node-positive disease after radical prostatectomy on biochemical recurrence and oncologic outcomes in men with prostate cancer.

Samuel L. Washington

Clinical utility of biomarkers 4K score, SelectMDx and ExoDx with MRI for the detection of high-grade prostate cancer.

Vittorio Fasulo

Contemporary racial disparities in PSA screening in a large, integrated health care system.

James T. Kearns

The deleterious association between proton pump inhibitors and prostate cancer specific death.

Hanan Goldberg

Prostate cancer survivorship care plans: What we are failing to tell men after treatment?

Youngjee Choi

A prospective comparison of MRI-planned versus CT-planned radiotherapy for prostate cancer.

Daniel R Schmidt

A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy (RT) for intermediate and high-risk prostate cancer (PC): Quality-of-life results (QoL) in SPCG-13 trial.

Pirkko-Liisa Kellokumpu-Lehtinen

Quality of life outcomes from a phase III trial exploring optimal sequencing of androgen deprivation therapy with external beam radiotherapy in localized prostate cancer.

Soumyajit Roy

A randomized phase II study of apalutamide (APA), androgen deprivation therapy (ADT), or APA + ADT in patients (pts) with biochemically relapsed (BCR) prostate cancer (PC).

Rahul Raj Aggarwal

A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).

Ashley Ross

Phase II trial of definitive radiotherapy with leuprolide and enzalutamide in high-risk prostate cancer.

Claire Marie de la Calle

Eight-year outcomes of a phase III randomized trial of conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): Update from the CHHiP Trial.

David P. Dearnaley

Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, survival, and late toxicity outcomes.

Andrew Loblaw

The risk of death from prostate cancer in men with Gleason Score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapy.

David Dewei Yang

Stereotactic body radiation therapy with androgen deprivation therapy for unfavorable-risk prostate cancer.

Sagar Anil Patel

Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521.

Howard M. Sandler

Phase II trial of neoadjuvant chemohormonal therapy (NAC) in prostate cancer (PC) with response assessment using PSMA PET/MRI.

Christos Kyriakopoulos

A systematic review and network meta-analysis of FDA approved treatment options in men with nonmetastatic, castration-resistant prostate cancer (M0CRPC).

Irbaz Bin Riaz

Biopsy positivity in prostate cancer patients undergoing mpMRI-targeted radiation dose escalation.

Jessica Meshman

Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design.

Vinayak Muralidhar

Loss of SNAI2 in prostate cancer and effect on patient response to androgen deprivation therapy.

Niall Corcoran

Predicting radiation-induced immune trafficking and activation in localized prostate cancer.

Scott Williams

Periprostatic venous androgen levels in a subset of patients with prostate cancer: An investigation into a novel role of testosterone in localized prostate cancer.

Lewis Thomas

Immunosuppressive milieu of high-risk localized prostate cancer.

Victor Ricardo Adorno Febles

Trends and oncological outcome of testosterone recovery after androgen deprivation therapy in prostate cancer patients who received external beam radiotherapy.

Akinori Takei

Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness.

Goutam Chakraborty

Tumor cell intrinsic androgen biosynthesis by 3β-hydroxy steroid dehydrogenase (HSD3B1) to modulate radiosensitivity in prostate cancer cells.

Shinjini Ganguly

Outcomes of men with ductal prostate cancer undergoing definitive therapy for localized disease.

Weranja Kalana Bodhisiri Ranasinghe

Early diagnosis of prostate cancer, AABH (Aspartyl Asparaginyl β-hydroxylase), a predictive biomarker: A serum immunoassay and personalized medicine.

Kiarash Moshiri

Natural history of an immediately detectable PSA following radical prostatectomy: A description of a contemporary cohort.

Peter Eoin Lonergan

Influence of caseload on survival of patients (pts) with localized prostate cancer (PC) after definitive radiation therapy (DRT).

Sarmad Sadeghi

Association of salvage cryoablation with decreased utilization of androgen deprivation therapy for recurrent prostate cancer after radiotherapy.

J Kellogg Parsons

Treatment timing in localized high-risk prostate cancer treated with radiation and androgen deprivation therapy.

Shaakir Hasan

Physical activity assessment among men undergoing genetic counseling for inherited prostate cancer: A teachable moment.

Veda N. Giri

The relationship between socioeconomic status and treatment for prostate cancer in a universal healthcare system: A population-based analysis.

Justin Oake

Rates and determinants of prostatectomy in prostate cancer (PCa) patients with node-positive disease.

Lova Sun

The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation.

Jehonathan H. Pinthus

Stereotactic body radiotherapy boost toxicity for high and intermediate-risk prostate cancer: Report of a multi-institutional study.

Irving D. Kaplan

Adjuvant radiotherapy following radical prostatectomy for prostate cancer: A systematic review and meta-analysis.

Tobias Engel Ayer Botrel

Redefining the role of adjuvant versus salvage radiation therapy for prostate cancer after radical prostatectomy for T3 disease and/or positive margins.

Barry W. Goy

A tale of lineage plasticity: Intense neoadjuvant testosterone lowering therapy in localized prostate cancer (PCa) harboring high-risk genomic signatures.

Fatima Karzai

The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: A systematic review and meta-analysis.

Zhipeng Wang

Utilization of androgen deprivation therapy (ADT) and stereotactic body radiation therapy (SBRT) for localized prostate cancer (PC) in the United States (US).

Trevor Joseph Royce

Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy.

Avinash Pilar

Stereotactic radiotherapy +/- HDR boost for unfavorable-risk prostate cancer: Comparison of efficacy, survival, and late toxicity outcomes.

Andrew Loblaw

Adjuvant docetaxel after definitive radiotherapy for high-risk prostate cancer: A meta-analysis of randomized clinical trials.

Ray Manneh Kopp

High-dimensional single cell-based immune profiling of the tumor immune microenvironment in prostate cancer.

Michela Masetti

Significance of distinct specifically enriched missense TP53 mutations in prostate cancer.

Irina Vasilevskaya

Evaluation of the oncologic benefit of adjunctive surgery at time of postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).

Tim Nestler

Validation of the two best models to predict “benign” pathohistology in patients with advanced nonseminomatous germ cell tumors (NSGCT) undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).

Tim Nestler

The use of DNA promoter methylation testing for prostate cancer diagnosis in the Department of Veterans Affairs.

Kyung Min Lee

Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).

Alexander P. Kenigsberg

A multicenter phase II study of avelumab in patients with locally advanced or metastatic penile cancer (PC) who are unfit for, or have progressed on or after platinum-based chemotherapy: (ALPACA).

Husam Alqaisi

Phase 0 study to assess [111In]-DOTA-h11B6 to target human kallikrein-2 (hk2) in men with metastatic castration-resistant prostate cancer.

Michael J. Morris

A phase I study to evaluate PSCA-targeting chimeric antigen receptor (CAR)-T cells for patients with PSCA+ metastatic castration-resistant prostate cancer (mCRPC).

Tanya B. Dorff

Single-arm, phase II study to evaluate the safety and efficacy of sacituzumab govitecan in patients with metastatic castration-resistant prostate cancer who have progressed on second generation AR-directed therapy.

Joshua Michael Lang

A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Atish Dipankar Choudhury

Targeting resistant prostate cancer with ATR and PARP inhibition (TRAP trial): A phase II study.

Zachery R. Reichert

A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Wassim Abida

Phase III study of pembrolizumab (pembro) plus olaparib versus enzalutamide (enza) or abiraterone acetate (abi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed on chemotherapy: KEYLYNK-010.

Evan Y. Yu

Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) versus placebo plus enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641.

Julie Nicole Graff

VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

A. Oliver Sartor

A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-a

Evan Y. Yu

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC).

Ben Tran

Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)–pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921.

Daniel Peter Petrylak

TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal

Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: A sub-study of the VISION trial.

Jens Kurth

A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

David Johnson Einstein

Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response.

Benjamin Louis Maughan

A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388).

Ulka N. Vaishampayan

A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.

Vivek Narayan

A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer.

Akash Patnaik

A phase Ib/II, open-label, platform study evaluating the efficacy and safety of AB928-based treatment combinations in participants with metastatic castrate-resistant prostate cancer.

David R. Wise

Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) and nivolumab (Nivo) in patients (pts) with nonmetastatic, PSA-recurrent prostate cancer (PCa).

Hamid Emamekhoo

A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC).

Michael C. Burn

Chemokine signaling and MAPK/ERK pathway for advanced prostate cancer treatment response.

Yazan Numan

A phase Ib/II trial of perioperative intratumoral MVA-BN-brachyury (MVA) plus systemic PROSTVAC and atezolizumab (Atezo) for intermediate-risk and high-risk localized prostate cancer (AtezoVax).

Benjamin Louis Maughan

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced pr

Mary-Ellen Taplin

DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive

Tamim Niazi